41420-90-0

Basic information

• Product Name: 2-(4-bromophenyl)-1,3,4-oxadiazole
• Synonyms: 2-(4-bromophenyl)-1,3,4-oxadiazole;UKRORGSYN-BB BBV-065462;2-(4-bromophenyl)-1,3,4-oxadiazole(SALTDATA: FREE);2-(4-Bromophenyl)-1,3,4-oxadiazole 97%
• CAS NO: 41420-90-0
• Molecular Formula: C₈H₅BrN₂O
• Molecular Weight: 225.05
• Mol File: 41420-90-0.mol
• Article Data: 22

Chemical Properties

• Melting Point: 142-147°C
• Boiling Point: 303.1°C at 760 mmHg
• Flash Point: 137.1°C
• Appearance: /
• Density: 1.605g/cm³
• Vapor Pressure: 0.0017mmHg at 25°C
• Refractive Index: 1.585
• PKA: -4.67±0.32(Predicted)
• CAS DataBase Reference: 2-(4-bromophenyl)-1,3,4-oxadiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-bromophenyl)-1,3,4-oxadiazole(41420-90-0)
• EPA Substance Registry System: 2-(4-bromophenyl)-1,3,4-oxadiazole(41420-90-0)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• Hazardous Substances Data: 41420-90-0(Hazardous Substances Data)

Usage

General Description

2-(4-bromophenyl)-1,3,4-oxadiazole is a chemical compound with the molecular formula C8H5BrN2O. It belongs to the oxadiazole family and is commonly used in the field of organic chemistry and pharmaceutical research. 2-(4-bromophenyl)-1,3,4-oxadiazole is characterized by its aromatic ring containing a bromine atom and an oxadiazole moiety, which gives it certain biological and pharmacological properties. It is often used as a building block in the synthesis of various pharmaceuticals and organic compounds, due to its versatile reactivity and ability to undergo various chemical reactions. Its unique structure makes it a valuable intermediate in the production of drugs and other fine chemicals. Additionally, it is also utilized as a fluorescent probe in biochemical and medicinal studies due to its fluorescent properties.

InChI:InChI=1/C8H5BrN2O/c9-7-3-1-6(2-4-7)8-11-10-5-12-8/h1-5H

Upstream product

• 122-51-0 orthoformic acid triethyl ester 
• 5933-32-4 4-bromobenzoic acid hydrazide 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 149-73-5 trimethyl orthoformate 
• 586-76-5 4-Bromobenzoic acid 
• 73789-56-7 N-isocyaniminotriphenylphosphorane 
• 108-24-7 acetic anhydride 
• 1895-39-2 sodium chlorodifluoroacetate 
• 68-12-2 N,N-dimethyl-formamide 
• 589-87-7 1,4-bromoiodobenzene 
• 1258867-73-0 (1,3,4-oxadiazol-2-yl)boronic acid 
• 5798-75-4 Ethyl 4-bromobenzoate 
• 536-74-3 phenylacetylene 
• 100-42-5 styrene 

Downstream Products

• 197074-72-9 N-(3,4-Dimethyl-5-isoxazolyl)-N-[(2-methoxyethoxy)methyl]-4'-(1,3,4-oxadiazol-2-yl)[1,1'-biphenyl]-2-sulfonamide 
• 276694-22-5 [4-(1,3,4-oxadiazol-2-yl) phenyl]boronic acid 
• 41421-19-6 5-(4-bromo-phenyl)-[1,3,4]-oxadiazole-2-thiol 

Relevant articles and documents

Copper-Catalyzed Enantioconvergent Cross-Coupling of Racemic Alkyl Bromides with Azole C(sp2)?H Bonds

The development of enantioconvergent cross-coupling of racemic alkyl halides directly with heteroarene C(sp2)?H bonds has been impeded by the use of a base at elevated temperature that leads to racemization. We herein report a copper(I)/cinchona-alkaloid-derived N,N,P-ligand catalytic system that enables oxidative addition with racemic alkyl bromides under mild conditions. Thus, coupling with azole C(sp2)?H bonds has been achieved in high enantioselectivity, affording a number of potentially useful α-chiral alkylated azoles, such as 1,3,4-oxadiazoles, oxazoles, and benzo[d]oxazoles as well as 1,3,4-triazoles, for drug discovery. Mechanistic experiments indicated facile deprotonation of an azole C(sp2)?H bond and the involvement of alkyl radical species under the reaction conditions.

Ligand-Enabled Palladium-Catalyzed Through-Space C?H Bond Activation via a Carbopalladation/1,4-Pd Migration/C?H Functionalization Sequence

We report, herein, a palladium-catalyzed cascade comprising carbopalladation, 1,4-Pd-migration and C(sp2)?C(sp2) bond formation to construct a variety of bis-heterocyclic frameworks in a single operational step. The methodology provi

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.